Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ib/II study of MRG007 combination therapy in advanced colorectal cancer
CTR20263021Phase 2Active
- Sponsor
- Lepu Biopharma Co., Ltd.
- Start
- Sep 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of MRG007 in colorectal adenocarcinoma, sponsored by Lepu Biopharma Co., Ltd.. Started Sep 2026; status: active.
02
Drugs
MRG007
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on CTR20263021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263021.